VZV T cell-mediated immunity

Current Topics in Microbiology and Immunology

Volumn 342, Issue 1, 2010, Pages 341-357

  Weinberg, Adriana ^a   Levin, Myron J ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CHICKENPOX VACCINE; VARICELLA ZOSTER VACCINE; HERPES VACCINE;

AGE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHICKENPOX; DRUG EFFICACY; HERPES ZOSTER; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; MEMORY T LYMPHOCYTE; NONHUMAN; PAIN; PRIORITY JOURNAL; RASH; SENSORY GANGLION; T LYMPHOCYTE; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION; WILD TYPE; IMMUNOLOGY; REVIEW; VIROLOGY;

HERPES ZOSTER; HUMAN HERPESVIRUS 3;

CHICKENPOX; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HERPESVIRUS VACCINES; HUMANS; IMMUNITY, CELLULAR; T-LYMPHOCYTES;

EID: 77952826222     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/82-2010-31     Document Type: Article

References (77)

1. Advisory Committee on Immunization Practices, C.f.D.C.a.P 2007) Recommendations of the ACIP on varicella immunization http://www.cdc.gov/mmwr/ preview/mmwrhtml/rr5604a1.htm
2. Arvin AM et al (1978) Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma. J Infect Dis 137(5):531-540 (Pubitemid 8331808)
3. Arvin AM, Koropchak CM, Wittek AE (1983) Immunologic evidence of reinfection with varicella-zoster virus. J Infect Dis 148(2):200-205 (Pubitemid 13002453)
4. Arvin AM et al (1986a) Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. J Infect Dis 154(3):422-429 (Pubitemid 16020114)
5. Arvin AM et al (1986b) Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. J Immunol 137(4):1346-1351 (Pubitemid 16041127)
6. Arvin AM et al (1991) Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. J Immunol 146(1):257-264
7. Arvin AM et al (2002) Memory cytotoxic T cell responses to viral tegument and regulatory proteins encoded by open reading frames 4, 10, 29, and 62 of varicella-zoster virus. Viral Immunol 15(3):507-516
8. Asano Y et al (1994) Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 94(4 Pt 1):524-526 (Pubitemid 24295036)
9. Asanuma H et al (2000) Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis 181(3):859-866 (Pubitemid 30194466)
10. Bergen RE et al (1991) Human T cells recognize multiple epitopes of an immediate early/ tegument protein (IE62) and glycoprotein I of varicella zoster virus. Viral Immunol 4(3):151-166
11. Bhaduri-McIntosh S et al (2008) Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines. Blood 111(3):1334-43 (Pubitemid 351213420)
12. Buchbinder SP et al (1992) Herpes zoster and human immunodeficiency virus infection. J Infect Dis 166(5):1153-1156
13. Burke BL et al (1982) Immune responses to varicella-zoster in the aged. Arch Intern Med 142(2):291-293 (Pubitemid 12180803)
14. Cambier J (2005) Immunosenescence: a problem of lymphopoiesis, homeostasis, microenvironment, and signaling. Immunol Rev 205:5-6
15. Chaves SS et al (2007) Loss of vaccine-induced immunity to varicella over time. N Engl J Med 356(11):1121-1129 (Pubitemid 46425596)
16. Diaz PS et al (1988) Immunity to whole varicella-zoster virus antigen and glycoproteins I and p170: relation to the immunizing regimen of live attenuated varicella vaccine. J Infect Dis 158(6):1245-1252 (Pubitemid 19023288)
17. Diaz PS et al (1989) T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol 142(2):636-641 (Pubitemid 19039988)
18. Frey CR et al (2003) Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination. J Infect Dis 188(1):40-52 (Pubitemid 36829740)
19. Galea SA et al (2008) The safety profile of varicella vaccine: a 10-year review. J Infect Dis 197 (Suppl 2):S165-S169 (Pubitemid 351590166)
20. Gershon AA, Steinberg SP (1979) Cellular and humoral immune responses to varicella-zoster virus in immunocompromised patients during and after varicella-zoster infections. Infect Immun 25(1):170-174 (Pubitemid 9226959)
21. Gershon AA, Steinberg SP, Gelb L (1986) Live attenuated varicella vaccine use in immunocompromised children and adults. Pediatrics 78(4 Pt 2):757-762 (Pubitemid 16007079)
22. Gershon AA et al (1997) Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection. J Infect Dis 176(6):1496-1500 (Pubitemid 27518149)
23. Giller RH, Winistorfer S, Grose C (1989) Cellular and humoral immunity to varicella zoster virus glycoproteins in immune and susceptible human subjects. J Infect Dis 160(6):919-928 (Pubitemid 20002757)
24. Good RA, Zak SJ (1956) Disturbances in gamma globulin synthesis as experiments of nature. Pediatrics 18(1):109-149
25. Hata A et al (2002) Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 347(1):26-34 (Pubitemid 34728954)
26. Hayward AR (1990) T-cell responses to predicted amphipathic peptides of varicella-zoster virus glycoproteins II and IV. J Virol 64(2):651-655 (Pubitemid 20032678)
27. Hayward A, Giller R, Levin M (1989) Phenotype, cytotoxic, and helper functions of T cells from varicella zoster virus stimulated cultures of human lymphocytes. Viral Immunol 2(3):175-184 (Pubitemid 19275650)
28. Hayward AR, Zerbe GO, Levin MJ (1994a) Clinical application of responder cell frequency estimates with four years of follow up. J Immunol Methods 170(1):27-36
29. Hayward AR, Buda K, Levin MJ (1994b) Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults. Viral Immunol 7(1):31-36 (Pubitemid 24330461)
30. Hayward AR et al (1998) Cytokine production in varicella-zoster virus-stimulated cultures of human blood lymphocytes. J Infect Dis 178(Suppl 1):S95-S98 (Pubitemid 28514280)
31. Hope-Simpson RE (1965) The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 58:9-20
32. Jenkins DE et al (1998) Interleukin (IL)-10, IL-12, and interferon-gamma production in primary and memory immune responses to varicella-zoster virus. J Infect Dis 178(4):940-948 (Pubitemid 28452183)
33. Jones L et al (2006) Persistent high frequencies of varicella-zoster virus ORF4 protein-specific CD4+ T cells after primary infection. J Virol 80(19):9772-9778 (Pubitemid 44435651)
34. Kittan NA et al (2007) Impaired plasmacytoid dendritic cell innate immune responses in patients with herpes virus-associated acute retinal necrosis. J Immunol 179(6):4219-4230
35. Kost RG, Straus SE (1996) Postherpetic neuralgia-pathogenesis, treatment, and prevention. N Engl J Med 335(1):32-42
36. Kumagai T et al (1980) Development and characteristics of the cellular immune response to infection with varicella-zoster virus. J Infect Dis 141(1):7-13 (Pubitemid 10133828)
37. Kumagai T et al (1999) Varicella-zoster virus-specific cellular immunity in subjects given acyclovir after household chickenpox exposure. J Infect Dis 180(3):834-837 (Pubitemid 29411372)
38. Kuter B et al (2004) Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 23(2):132-137 (Pubitemid 38222785)
39. Lange J et al (2006) Immunogenicity, kinetics of VZV-specific CD4+ T-cell g-IFN production and safety of a live attenuated Oka/Merck zoster vaccine in healthy adults-60 years of age. Abstract #857, in 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Toronto, Canada
40. Levin MJ et al (1992) Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 166(2):253-259
41. Levin MJ et al (1994) Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine. J Infect Dis 170(3):522-526 (Pubitemid 24262250)
42. Levin MJ et al (1998) Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 178(Suppl 1):S109-S112 (Pubitemid 28514283)
43. Levin MJ et al (2006) Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J Infect Dis 194(2):247-255 (Pubitemid 44087197)
44. Levin MJ et al (2008a) Herpes zoster with skin lesions and meningitis caused by 2 different genotypes of the Oka varicella-zoster virus vaccine. J Infect Dis 198(10):1444-1447
45. Levin MJ et al (2008b) Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 197(6):825-835 (Pubitemid 351417005)
46. Levy O et al (2003) Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis 188(7):948-953 (Pubitemid 37268242)
47. Malavige GN et al (2007) Rapid effector function of varicella-zoster virus glycoprotein I-specific CD4+ T cells many decades after primary infection. J Infect Dis 195(5):660-664
48. Malavige GN et al (2008) Viral load, clinical disease severity and cellular immune responses in primary varicella zoster virus infection in Sri Lanka. PLoS One 3(11):e3789
49. Merck Varivax Package Insert (2009) www.merck.com/product/USA/pi- circular/v/varivax/ varivax-pi.pdf
50. Michalik DE et al (2008) Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis 197(7):944-949 (Pubitemid 351590021)
51. Morrow G et al (2003) Varicella-zoster virus productively infects mature dendritic cells and alters their immune function. J Virol 77(8):4950-4959 (Pubitemid 36402843)
52. Nader S et al (1995) Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis 171(1):13-17
53. Ngai AL et al (1996) Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. Pediatr Infect Dis J 15(1):49-54 (Pubitemid 26029243)
54. Onozawa M et al (2006) Relationship between preexisting anti-varicella-zoster virus (VZV) antibody and clinical VZV reactivation in hematopoietic stem cell transplantation recipients. J Clin Microbiol 44(12):4441-4443 (Pubitemid 44937077)
55. Oxman MN et al (2005) A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352(22):2271-2284
56. Patterson-Bartlett J et al (2007) Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine 25(41):7087-7093 (Pubitemid 47464679)
57. Rotbart HA, Levin MJ, Hayward AR (1993) Immune responses to varicella zoster virus infections in healthy children. J Infect Dis 167(1):195-199 (Pubitemid 23002857)
58. Sadaoka K et al (2008) Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay. J Infect Dis 198(9):1327-1333
59. SharpMet al (1992) Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. J Infect Dis 165(5):852-858
60. Son M et al (2008) Vaccination of children with perinatal HIV infection protects against varicella and zoster. In: Pediatric Academic Societies and Asian Society for Pediatric Research joint meeting. Honolulu, Hawaii
61. Takahashi M (1984) Development and characterization of a live varicella vaccine (Oka strain). Biken J 27(2-3):31-36 (Pubitemid 15167918)
62. Takahashi M et al (2008) Development of varicella vaccine. J Infect Dis 197(Suppl 2):S41-S44 (Pubitemid 351590143)
63. Trannoy E et al (2000) Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine 18(16):1700-1706 (Pubitemid 30109532)
64. Varis T, Vesikari T (1996) Efficacy of high-titer live attenuated varicella vaccine in healthy young children. J Infect Dis 174(Suppl 3):S330-S334 (Pubitemid 26357217)
65. Verjans GM et al (2007) Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci USA 104(9):3496-3501 (Pubitemid 46364187)
66. Vessey SJ et al (2001) Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy. J Pediatr 139(2):297-304 (Pubitemid 32721721)
67. Vossen MT et al (2004) Development of virus-specific CD4+ T cells on reexposure to Varicella-Zoster virus. J Infect Dis 190(1):72-82 (Pubitemid 38858406)
68. Vossen MT et al (2005) Absence of circulating natural killer and primed CD8+ cells in lifethreatening varicella. J Infect Dis 191(2):198-206 (Pubitemid 40096377)
69. Watson B et al (1990) Cell-mediated immune responses after immunization of healthy seronegative children with varicella vaccine: kinetics and specificity. J Infect Dis 162(4):794-799 (Pubitemid 20336514)
70. Watson B et al (1995a) Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis 20(2):316-319
71. Watson B et al (1995b) Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J Infect Dis 172(1):217-219
72. Weinberg A et al (2009) Varicella-Zoster Virus-Specific Immune Responses to Herpes Zoster in Elderly Participants in a Trial of a Clinically Effective Zoster Vaccine. J Infect Dis 200 (7):1068-1077
73. White CJ et al (1992) Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 11(1):19-23
74. Wilson A et al (1992) Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 165(1):119-126
75. Yawn BP et al (2007) A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 82(11):1341-1349 (Pubitemid 350060129)
76. Zhang Y et al (1994) Cytokine production in varicella zoster virus-stimulated limiting dilution lymphocyte cultures. Clin Exp Immunol 98(1):128-133 (Pubitemid 24315463)
77. Zhu J et al (2007) Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 204(3):595-603 (Pubitemid 46457082)